Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

351 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Tamura K, et al. Among authors: katsumata n. Ann Oncol. 2011 Jun;22(6):1302-1307. doi: 10.1093/annonc/mdq585. Epub 2010 Nov 25. Ann Oncol. 2011. PMID: 21109570 Clinical Trial.
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).
Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, Masuda N, Andoh J, Ikeda T, Shibata T, Takashima S. Katsumata N, et al. Ann Oncol. 2009 Jul;20(7):1210-5. doi: 10.1093/annonc/mdn781. Epub 2009 Mar 2. Ann Oncol. 2009. PMID: 19254942 Clinical Trial.
351 results